• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Fitzpatrick Margaret M

    9/10/24 5:00:07 PM ET
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTGN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FitzPatrick Margaret M

    (Last) (First) (Middle)
    C/O VISTAGEN THERAPEUTICS, INC.
    343 ALLERTON AVENUE

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vistagen Therapeutics, Inc. [ VTGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/06/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $3.25 09/06/2024 A 14,100 (1) 09/06/2034 Common Stock 14,100 $0 14,100 D
    Explanation of Responses:
    1. Represents stock options ("Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Twenty-five percent (25%) of the Options vest on the date of issuance ("Grant Date"), with the remainder vesting in twelve (12) equal monthly installments thereafter, until the Options become fully vested on the one (1) year anniversary of the Grant Date.
    /s/ Cynthia Anderson, Attorney-in-Fact 09/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VTGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTGN

    DatePrice TargetRatingAnalyst
    12/7/2023$15.00Hold → Buy
    Jefferies
    8/7/2023$30.00Hold → Buy
    Maxim Group
    7/22/2022Outperform → Neutral
    Robert W. Baird
    7/22/2022Buy → Hold
    Jefferies
    7/22/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $VTGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

      New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company's poster presentations examined the age of onset of SAD in participants in the Company's fasedieno

      4/17/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Present at the 2025 Anxiety and Depression Association Conference

      Posters Highlight New Insights into Social Anxiety Disorder Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company's poster presentations will explore the age of onset of social anxiety disorder (SAD) from participants in fasedienol clinical trials, and new data on the characteristics of young adults with and without SAD. Poster Presentations: Date: Friday, April 4, 2025,

      3/19/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Participate in Stifel 2025 Virtual CNS Forum

      Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel's 2025 Virtual CNS Forum. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m. Eastern Time. A live webcast will be accessible through the "Events" page in the "Investors" section of the Company's website at www.Vistagen.com. A replay of the webcast will be archived and available following the event. About Vistagen Hea

      3/4/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Financials

    Live finance-specific insights

    See more
    • Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

      Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 202

      2/13/25 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

      Vistagen (NASDAQ:VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update. The conference call is being webcast live and a link can be found under "Events" in the Investors section of the Company's website. Participants may register for the live call link HERE to receive the dial-in numbers and uni

      2/6/25 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

      Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway Vistagen (NASDAQ:VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute treatment of social anxiety disorder," said Shawn Singh, Ch

      11/7/24 4:20:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Prince Joshua S. was granted 3,310 shares, increasing direct ownership by 124% to 5,981 units (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      1/13/25 5:40:58 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 2,592 shares, increasing direct ownership by 72% to 6,184 units (SEC Form 4)

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      1/13/25 5:39:30 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cunningham Ann Michelle

      4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)

      9/10/24 5:00:10 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • VistaGen upgraded by Jefferies with a new price target

      Jefferies upgraded VistaGen from Hold to Buy and set a new price target of $15.00

      12/7/23 6:31:15 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen upgraded by Maxim Group with a new price target

      Maxim Group upgraded VistaGen from Hold to Buy and set a new price target of $30.00

      8/7/23 2:16:37 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VistaGen downgraded by Robert W. Baird

      Robert W. Baird downgraded VistaGen from Outperform to Neutral

      7/22/22 12:22:03 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    SEC Filings

    See more
    • Vistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)

      3/6/25 4:51:39 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.

      SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/25 4:40:23 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vistagen Therapeutics Inc.

      SCHEDULE 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/25 4:28:38 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

      Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health Vistagen (NASDAQ:VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join toget

      10/9/24 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Appoints Cindy Anderson as Chief Financial Officer

      Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen Vistagen (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. "We are delighted to welcome Ms. Anderson, an experienced and highly accomplished finance professional, to our team," said Shawn Singh, Chief Executive Officer of V

      8/22/23 8:30:00 AM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022

      Annual Meeting to resume October 28, 2022 to vote on Proposal No. 5 to provide Vistagen's Board of Directors the option to implement a future reverse stock split of the Company's issued and outstanding common stock, if necessary to maintain the Company's listing on the Nasdaq Capital Market, and Proposal No. 6 to allow for an amendment to the Company's Bylaws Vistagen Therapeutics, Inc. (NASDAQ:VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced results of voting and the partial adjournment of the Company's 2022 Annua

      10/19/22 4:30:00 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      11/14/24 5:05:41 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vistagen Therapeutics Inc.

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      11/14/24 4:19:46 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by VistaGen Therapeutics Inc. (Amendment)

      SC 13G/A - Vistagen Therapeutics, Inc. (0001411685) (Subject)

      2/14/24 6:18:34 PM ET
      $VTGN
      Biotechnology: Pharmaceutical Preparations
      Health Care